Which laboratory tests should be ordered for evaluation of a complex ovarian mass identified on imaging?

Laboratory Testing for Complex Ovarian Mass

For a complex ovarian mass identified on imaging, you should order CA-125 as the primary tumor marker, and add CA-19-9 and CEA specifically if mucinous histology is suspected or to help distinguish ovarian from gastrointestinal primary tumors 1, 2.

Core Laboratory Panel

Primary Tumor Marker

• CA-125: This is the standard serum marker for suspected ovarian malignancy 1, 2
  • Elevated in ~85% of advanced ovarian cancer (stage II or greater) 1
  • Only ~50% sensitive in stage I disease 1, 3
  • Important caveat: Can be falsely elevated in benign conditions (endometriosis, benign cysts, pregnancy, pelvic inflammatory disease, cirrhosis, pancreatic cancer) 1
  • In menstruating women, false positives are particularly common 1

Additional Markers for Specific Scenarios

If mucinous tumor suspected or gastrointestinal origin unclear:

• CA-19-9 and CEA 1, 2
  • A CA-125/CEA ratio >25:1 optimizes specificity for ovarian versus gastrointestinal primary 1
  • If CA-125/CEA ratio is ≤25, consider endoscopy (colonoscopy/gastroscopy) to rule out GI primary 2, 3

In young women (reproductive age):

• Alpha-fetoprotein (AFP) and beta-hCG 4
  • Essential to exclude germ cell tumors, which have different treatment implications and better prognosis

Important Clinical Considerations

Menopausal Status Matters

The utility of CA-125 varies significantly:

• Postmenopausal women: CA-125 is more useful as a discriminator between benign and malignant masses 5
• Premenopausal women: CA-125 has limited value due to frequent false positives from physiologic conditions 1, 6

When CA-125 Adds Limited Value

CA-125 performs poorly for:

• Low-grade malignancies 7
• Borderline tumors 7
• Early-stage disease 1

Critical point: CA-125 improves specificity only in lesions already suspected to be malignant on ultrasound 7. It should not be used in isolation but rather as part of comprehensive assessment with imaging findings.

Integration with Imaging

The combination of ultrasound morphology and tumor markers is superior to either alone:

• Complex cysts >5 cm in postmenopausal women with elevated CA-125 carry high malignancy risk 6
• In premenopausal women, malignancy occurs almost exclusively in complex cysts >5 cm, regardless of CA-125 level 6

What NOT to Order Routinely

• Spectral Doppler parameters (resistive index, pulsatility index): These do not add significant value beyond morphologic ultrasound assessment 7
• HE4 (human epididymis protein 4): Not recommended as standard; ultrasound-based models (IOTA) are superior 2

Practical Algorithm

1. All patients with complex ovarian mass: Order CA-125
2. If imaging suggests mucinous features OR CA-125/CEA ratio needed: Add CA-19-9 and CEA
3. If patient <40 years old: Add AFP and beta-hCG to exclude germ cell tumor
4. If CA-125/CEA ratio ≤25: Refer for GI endoscopy to exclude metastatic disease from GI primary

This targeted approach avoids unnecessary testing while capturing the most clinically relevant information for surgical planning and referral decisions 1, 2.